Compare · GRPH vs PXMD
GRPH vs PXMD
Side-by-side comparison of Graphite Bio Inc. (GRPH) and PaxMedica Inc. (PXMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRPH and PXMD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- GRPH has more recent analyst coverage (16 ratings vs 0 for PXMD).
- Company
- Graphite Bio Inc.
- PaxMedica Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2022
- News (4w)
- 0
- 0
- Recent ratings
- 16
- 0
Graphite Bio Inc.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Latest GRPH
- Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)
- SEC Form 424B3 filed by Graphite Bio Inc.
- SEC Form 10-Q filed by Graphite Bio Inc.
- Graphite Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form EFFECT filed by Graphite Bio Inc.
- SEC Form 424B3 filed by Graphite Bio Inc.
- SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)
- Graphite Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form S-1 filed by Graphite Bio Inc.
- New insider Alpha Wave Ventures Gp, Ltd claimed ownership of 3,612,211 shares (SEC Form 3)
Latest PXMD
- PaxMedica Inc. filed SEC Form 8-K: Leadership Update
- PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
- Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.
- SEC Form NT 10-Q filed by PaxMedica Inc.
- SEC Form EFFECT filed by PaxMedica Inc.
- SEC Form S-1 filed by PaxMedica Inc.
- SEC Form 10-Q filed by PaxMedica Inc.
- PaxMedica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits
- PaxMedica Secures Immediate Exercise of Warrants
- PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection